Test Your Knowledge

Quiz: Is Pembrolizumab Plus Bevacizumab Beneficial for Metastatic RCC?

09/02/2020

Recent News

News

New Conceptual Model Captures Patient Experience in Polycythemia Vera

06/08/2026

Stephanie Holland

Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.

Results from a qualitative study...

06/08/2026

Oncology

News

Real-World Analysis Identifies Challenges With Phlebotomy-Based Management of Polycythemia Vera

06/08/2026

Stephanie Holland

Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.

Results from a retrospective...

06/08/2026

Oncology

News

Higher Starting Dose of Ropeginterferon Accelerates Responses in Patients With Polycythemia Vera

06/08/2026

Stephanie Holland

Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.

Results from a systematic review...

06/08/2026

Oncology

News

Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors

06/08/2026

Emily Estrada

Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.

Results from the phase 3...

06/08/2026

Oncology

News

Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors

06/08/2026

Emily Estrada

Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.

Results from a retrospective...

06/08/2026

Oncology

News

Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

06/05/2026

Emily Estrada

Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Results from a phase 1 study...

06/05/2026

Oncology

News

Fedratinib Demonstrates Potential Clinical Promise in Patients With Proliferative MDS/MPNs and Chronic Neutrophilic Leukemia

06/05/2026

Emily Estrada

Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.

Results from a phase 2 study...

06/05/2026

Oncology

News

Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma

06/05/2026

Emily Estrada

Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.

Results from a phase 2 study...

06/05/2026

Oncology

News

ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma

06/05/2026

Emily Estrada

Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.

Results from a phase 2 trial...

06/05/2026

Oncology

News

Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma

06/01/2026

Emily Estrada

Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.

Results from the...

06/01/2026

Oncology